{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:58:07Z","timestamp":1787021887325,"version":"build-2736575974"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T00:00:00Z","timestamp":1366329600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061537","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T17:10:50Z","timestamp":1366391450000},"page":"e61537","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":129,"title":["Metformin Downregulates the Insulin\/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners"],"prefix":"10.1371","volume":"8","author":[{"given":"Rive","family":"Sarfstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Attias-Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,4,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ejso.2006.03.046","article-title":"Management of endometrial cancer","volume":"32","author":"H Kitchener","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ejca.2011.09.014","article-title":"p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy","volume":"48","author":"Z Attias-Geva","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/path.1666","article-title":"Abnormalities in the NF-kappa B family and related proteins in endometrial carcinoma","volume":"204","author":"J Pallares","year":"2004","journal-title":"J Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00441-005-1109-5","article-title":"Endometrial cancer","volume":"322","author":"AJ Ryan","year":"2005","journal-title":"Cell Tissue Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2337\/dc10-0979","article-title":"Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18)","volume":"33","author":"GW Landman","year":"2010","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1002\/cncr.21866","article-title":"Association between adiponectin, insulin resistance, and endometrial cancer","volume":"106","author":"PT Soliman","year":"2006","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1028-4559(08)60102-3","article-title":"Molecular carcinogenesis of endometrial cancer","volume":"46","author":"FS Liu","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"ref8","first-page":"1531","article-title":"Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review","volume":"11","author":"R Kaaks","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-10-2243","article-title":"Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth","volume":"17","author":"GZ Rocha","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2008.01.007","article-title":"Targeting AMPK: a new therapeutic opportunity in breast cancer","volume":"67","author":"SM Hadad","year":"2008","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4161\/cc.8.6.7933","article-title":"Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro","volume":"8","author":"IN Alimova","year":"2009","journal-title":"Cell Cycle"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"M Guba","year":"2002","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"M Hidalgo","year":"2000","journal-title":"Oncogene"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nm1120","article-title":"Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model","volume":"10","author":"L Uhrbom","year":"2004","journal-title":"Nature Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"P Frost","year":"2004","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1073\/pnas.0502256102","article-title":"A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance","volume":"102","author":"D Xing","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13813450902783106","article-title":"The insulin-like growth factor-I receptor as an oncogene","volume":"115","author":"H Werner","year":"2009","journal-title":"Arch Physiol Biochem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/14728220903201702","article-title":"Targeting the IGF1 axis in cancer proliferation","volume":"13","author":"I Bruchim","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2013implications for a novel treatment strategy","volume":"116","author":"LA Cantrell","year":"2010","journal-title":"Gynecol Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsbmb.2010.12.006","article-title":"Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells","volume":"126","author":"Y Xie","year":"2011","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref21","first-page":"2","article-title":"For debate: the pathophysiological significance of IGF-I receptor overexpression: new insights","volume":"7","author":"H Werner","year":"2009","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/14728220903201702","article-title":"Targeting the IGF1 axis in cancer proliferation","volume":"13","author":"I Bruchim","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"M Pollak","year":"2008","journal-title":"Nature Rev Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/onc.2011.447","article-title":"Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer","volume":"31","author":"H Werner","year":"2012","journal-title":"Oncogene"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-07-2686","article-title":"A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer","volume":"17","author":"MJ Gunter","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/annonc\/dkg022","article-title":"Dietary glycemic index, glycemic load and ovarian cancer risk: a case-control study in Italy","volume":"14","author":"LS Augustin","year":"2003","journal-title":"Ann Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"G Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e24468","DOI":"10.1371\/journal.pone.0024468","article-title":"The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway","volume":"6","author":"R Sarfstein","year":"2011","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/cancers2020233","article-title":"Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells","volume":"2","author":"R Sarfstein","year":"2010","journal-title":"Cancers"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1073\/pnas.86.1.114","article-title":"Structure of the human insulin receptor gene and characterization of its promoter","volume":"86","author":"S Seino","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/cyto.990030503","article-title":"A Detergent-Trypsin Method for the Preparation of Nuclei for Flow Cytometric DNA Analysis","volume":"3","author":"LL Vindelov","year":"1983","journal-title":"Cytometry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The two TORCs and Akt","volume":"12","author":"PT Bhaskar","year":"2007","journal-title":"Dev Cell"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"DA Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-010-0763-9","article-title":"Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells","volume":"123","author":"M Zakikhani","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mce.2006.03.018","article-title":"Transcriptional regulation of the insulin-like growth factor-1 receptor in breast cancer","volume":"252","author":"R Sarfstein","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1152\/japplphysiol.00194.2004","article-title":"Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70","volume":"97","author":"JG Kiang","year":"2004","journal-title":"J Appl Physiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bcp.2009.12.011","article-title":"AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress","volume":"79","author":"SH Choi","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"E891","DOI":"10.1152\/ajpendo.00176.2006","article-title":"Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue","volume":"291","author":"TP Ciaraldi","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2010.01.086","article-title":"Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4","volume":"393","author":"J Song","year":"2010","journal-title":"Biochem Bioph Res Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"G Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"CJ Currie","year":"2009","journal-title":"Diabetologia"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"S Jiralerspong","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1447-0756.2011.01839.x","article-title":"Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression","volume":"38","author":"L Dong","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ygyno.2012.01.009","article-title":"Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway","volume":"125","author":"RK Hanna","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"M Hollstein","year":"1991","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/sj.bjc.6602214","article-title":"Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells","volume":"91","author":"X Jin","year":"2004","journal-title":"Br J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/gyno.1998.5089","article-title":"Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines","volume":"70","author":"RK Reynolds","year":"1998","journal-title":"Gynecol Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-5793(03)00535-0","article-title":"PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells","volume":"545","author":"S Kang-Park","year":"2003","journal-title":"FEBS Lett"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.onc.1207162","article-title":"PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells","volume":"23","author":"H Zhao","year":"2004","journal-title":"Oncogene"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2012.06.017","article-title":"DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination","volume":"127","author":"C Korch","year":"2012","journal-title":"Gynecol Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.bjc.6602480","article-title":"Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy","volume":"92","author":"AD Santin","year":"2005","journal-title":"Br J Cancer"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ejca.2011.02.019","article-title":"Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells","volume":"47","author":"Z Attias-Geva","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-2187-3-18","article-title":"Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1","volume":"3","author":"Y Zhuang","year":"2008","journal-title":"J Mol Signal"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CCO.0b013e32834d8155","article-title":"Metformin and cancer therapy","volume":"24","author":"F Bost","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"I Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"MA Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0962-8924(02)00042-9","article-title":"Insulin\/IGF and target of rapamycin signaling: a TOR de force in growth control","volume":"13","author":"S Oldham","year":"2003","journal-title":"Trends Cell Biol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yexcr.2004.08.001","article-title":"GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas\/APO-1) expression","volume":"300","author":"E Beurel","year":"2004","journal-title":"Exp Cell Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"51075","DOI":"10.1074\/jbc.M408607200","article-title":"Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase","volume":"279","author":"S Liu","year":"2004","journal-title":"J Biol Chem"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T01:01:56Z","timestamp":1588986116000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061537"}},"subtitle":[],"editor":[{"given":"Angel","family":"Nadal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,19]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061537","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,19]]}}}